Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunovaccine has presented positive results of a preclinical study testing the efficacy of combining CEL-2000, CEL-SCI's rheumatoid arthritis (RA) vaccine antigen, and DepoVax, Immunovaccine's vaccine enhancement and delivery platform.
Subscribe to our email newsletter
The study results showed the ‘CEL-2000-DepoVax’ combination considerably lessened the symptoms and slowed the progression of RA in the animal model with a single dose.
The two companies will continue their research efforts to further optimise the CEL-2000-DepoVax vaccine combination for possible testing in future Phase I clinical trials.
CEL-2000 has the potential to slow the progression of rheumatoid arthritis and the DepoVax vaccine delivery technology is amenable to manufacturing and scale up in a GMP setting, providing the potential for quicker clinical development, Immunovaccine said.
Immunovaccine Research and Development vice president Marc Mansour said that they are extremely pleased that CEL-2000, when delivered in our platform, proved efficacious with as little as one dose.
"These results provide further validation of the broad potential of our DepoVax vaccine delivery technology," Mansour said.